-
公开(公告)号：US20160046712A1
公开(公告)日：2016-02-18
申请号：US14665731
申请日：2015-03-23
Applicant: Novo Nordisk A/S - Novo Allé , Innate Pharma S.A.S.
Inventor： Søren Berg Padkær , Peter Andreas, Nicolai, Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjærgaard , Anders Svensson
IPC: C07K16/28
CPC classification number: C07K16/2803 , C07K16/28 , C07K2299/00 , C07K2317/55 , C07K2317/73 , C07K2317/76
Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.
Abstract translation: 本发明涉及能够通过减少抑制性KIR信号而不降低KIR与HLA-C的结合来增强NK介导的靶细胞杀伤的试剂和方法。 如本文所述，在KIR与其HLA I类配体结合时通过KIR转导负信号可涉及配体结合诱导的KIR分子的构象重构，允许在特定结构域中的相邻KIR之间形成相互作用，导致加速 聚类 提供了诸如单克隆抗体的方法和试剂，用于减少KIR介导的NK细胞细胞毒性的抑制，而不通过例如还原或阻断KIR的二聚化来降低或阻断HLA结合。
-
公开(公告)号：US20140023646A1
公开(公告)日：2014-01-23
申请号：US14043402
申请日：2013-10-01
Applicant: Innate Pharma S.A.S. , Novo Norkish A/S
IPC: A61K39/395 , A61K45/06
CPC classification number: A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/08 , C07K16/28 , C07K16/2803 , C07K16/2896 , C07K2317/24 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.
Abstract translation: 描述了使用阻断抑制性NK细胞受体的化合物治疗病毒性疾病的方法，从而降低其在杀死感染的靶细胞中NK细胞的细胞毒性的抑制。 在一个实施方案中，所述化合物是结合例如人KIR2DL1，KIR2DL2和KIR2DL3受体中的一种或多种的抗体。 在另一个实施方案中，所述方法还包括施用结合感染病毒的细胞上表达的抗原的治疗性抗体或融合蛋白。
-
公开(公告)号：US09018366B2
公开(公告)日：2015-04-28
申请号：US13745081
申请日：2013-01-18
Applicant: Novo-Nordisk A/S—Novo Allé , Innate Pharma S.A.S.
Inventor： Søren Berg Padkær , Peter Andreas Nicolai Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjærgaard , Anders Svensson
CPC classification number: C07K16/2803 , C07K16/28 , C07K2299/00 , C07K2317/55 , C07K2317/73 , C07K2317/76
Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.
Abstract translation: 本发明涉及能够通过减少抑制性KIR信号而不降低KIR与HLA-C的结合来增强NK介导的靶细胞杀伤的试剂和方法。 如本文所述，在KIR与其HLA I类配体结合时通过KIR转导负信号可涉及配体结合诱导的KIR分子的构象重构，允许在特定结构域中的相邻KIR之间形成相互作用，导致加速 聚类 提供了诸如单克隆抗体的方法和试剂，用于减少KIR介导的NK细胞细胞毒性的抑制，而不通过例如还原或阻断KIR的二聚化来降低或阻断HLA结合。
-
公开(公告)号：US08981065B2
公开(公告)日：2015-03-17
申请号：US13936486
申请日：2013-07-08
Applicant: Novo Nordisk A/S—Novo Alle , Innate Pharma S.A.S. , University of Genoa
Inventor： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagne , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thorolfsson , Soren Berg Padkaer , Kristian Kjaergaard , Pieter Johannes Louis Spee , Michael Wilken
CPC classification number: C07K16/42 , C07K16/28 , C07K16/2803 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。
-
Patent Agency Ranking
5.发明授权Methods of enhancing antibody-based antiviral therapies by administering KIR2DL-binding antibodies 有权通过施用KIR2DL结合抗体来增强基于抗体的抗病毒治疗的方法公开(公告)号：US09333255B2
公开(公告)日：2016-05-10
申请号：US14043402
申请日：2013-10-01
Applicant: Novo Norkisk A/S , Innate Pharma S.A.S.
IPC: C07K16/28 , C07K16/08 , A61K39/395 , A61K45/06 , A61K39/00
CPC classification number: A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/08 , C07K16/28 , C07K16/2803 , C07K16/2896 , C07K2317/24 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.
Abstract translation: 描述了使用阻断抑制性NK细胞受体的化合物治疗病毒性疾病的方法，从而降低其在杀死感染的靶细胞中NK细胞的细胞毒性的抑制。 在一个实施方案中，所述化合物是结合例如人KIR2DL1，KIR2DL2和KIR2DL3受体中的一种或多种的抗体。 在另一个实施方案中，所述方法还包括施用结合感染病毒的细胞上表达的抗原的治疗性抗体或融合蛋白。
-
公开(公告)号：US20150344576A1
公开(公告)日：2015-12-03
申请号：US14829170
申请日：2015-08-18
Applicant: Novo Nordisk A/S - Novo Alle , Innate Pharma S.A.S. , University of Genoa
Inventor： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagne , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thorolfsson , Soren Berg Padkaer , Kristian Kjaergaard , Pieter Johannes Louis Spee , Michael Wilken
IPC: C07K16/28
CPC classification number: C07K16/42 , C07K16/28 , C07K16/2803 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许哺乳动物受试者中NK细胞细胞毒性增强的抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。
-
公开(公告)号：US20150191547A1
公开(公告)日：2015-07-09
申请号：US14659045
申请日：2015-03-16
Applicant: Novo Nordisk A/S - Novo Alle , Innate Pharma S.A.S. , University of Genoa
Inventor： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagne , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thorolfsson , Soren Berg Padkaer , Kristian Kjaergaard , Pieter Johannes Louis Spee , Michael Wilken
IPC: C07K16/42
CPC classification number: C07K16/42 , C07K16/28 , C07K16/2803 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
-
公开(公告)号：US20130287770A1
公开(公告)日：2013-10-31
申请号：US13936486
申请日：2013-07-08
Applicant: INNATE PHARMA S.A.S. , NOVO-NORDISK A/S - NOVO ALLE
Inventor： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagne , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thorolfsson , Soren Berg Padkaer , Kristian Kjaergaard , Pieter Johannes Loius Spee , Milchael Wilken
IPC: C07K16/28
CPC classification number: C07K16/42 , C07K16/28 , C07K16/2803 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。
-
公开(公告)号：US20130143269A1
公开(公告)日：2013-06-06
申请号：US13745081
申请日：2013-01-18
Applicant: Novo-Nordisk A/S - Novo Allé , Innate Pharma S.A.S
Inventor： Søren Berg Padkaer , Peter Andreas, Nicolai, Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjaergaard , Anders Svensson
IPC: C07K16/28
CPC classification number: C07K16/2803 , C07K16/28 , C07K2299/00 , C07K2317/55 , C07K2317/73 , C07K2317/76
Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.
Abstract translation: 本发明涉及能够通过减少抑制性KIR信号而不降低KIR与HLA-C的结合来增强NK介导的靶细胞杀伤的试剂和方法。 如本文所述，在KIR与其HLA I类配体结合时通过KIR转导负向信号可涉及KIR分子的配体结合诱导的构象重新取向，允许在特定结构域中的相邻KIR之间形成相互作用，从而导致 加速聚类。 提供了诸如单克隆抗体的方法和试剂，用于减少KIR介导的NK细胞细胞毒性的抑制，而不通过例如还原或阻断KIR的二聚化来降低或阻断HLA结合。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.018 seconds)
